DTC
VKTX icon

Deep Track Capital’s Viking Therapeutics VKTX Stock Holding History

Deep Track Capital’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-610,083
Closed -$5.73M – 74
2022
Q4 		$5.73M Buy
+610,083
New +$2.72M 0.24% 49

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Deep Track Capital's VKTX Position: Q1 2023 in Review

Deep Track Capital sold out of Viking Therapeutics (VKTX) in Q1 2023, closing a stake of 610,083 shares — an estimated $5.73M sold.

Deep Track Capital first reported a position in VKTX in Q4 2022 and held it in 1 quarter. The position peaked at $5.73M in Q4 2022. 184 funds tracked by Wall St. Rank hold VKTX as of Q1 2023.

  • Deep Track Capital reported no remaining Viking Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Deep Track Capital sold 610,083 Viking Therapeutics shares in Q1 2023, an estimated $5.73M.
  • Deep Track Capital first reported a position in Viking Therapeutics in Q4 2022 and held it in 1 quarter.
  • Deep Track Capital's Viking Therapeutics position peaked at $5.73M in Q4 2022.
  • 184 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2023.

Based on Deep Track Capital's 13F filing for Q1 2023, filed 15 May 2023.